102 related articles for article (PubMed ID: 21529985)
1. Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry.
Hocker JR; Peyton MD; Lerner MR; Mitchell SL; Lightfoot SA; Lander TJ; Bates-Albers LM; Vu NT; Hanas RJ; Kupiec TC; Brackett DJ; Hanas JS
Lung Cancer; 2011 Nov; 74(2):206-11. PubMed ID: 21529985
[TBL] [Abstract][Full Text] [Related]
2. Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling.
Hocker JR; Lerner MR; Mitchell SL; Lightfoot SA; Lander TJ; Quillet AA; Hanas RJ; Peyton MD; Postier RG; Brackett DJ; Hanas JS
Cancer Invest; 2011 Feb; 29(2):173-9. PubMed ID: 21261478
[TBL] [Abstract][Full Text] [Related]
3. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
4. Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.
Hocker JR; Bishop EA; Lightfoot SA; Lerner MR; Peyton MD; Brackett DJ; Hanas RJ; McMeekin DS; Walker JL; Hanas JS
Cancer Invest; 2012 Feb; 30(2):189-97. PubMed ID: 22149058
[TBL] [Abstract][Full Text] [Related]
5. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.
Hanas JS; Peyton MD; Lerner MR; Lightfoot SA; Deb SJ; Hanas RJ; Vu NT; Kupiec TC; Stowell DE; Brackett DJ; Dubinett SM; Hocker JR
Cancer Invest; 2014 May; 32(4):136-43. PubMed ID: 24579933
[TBL] [Abstract][Full Text] [Related]
6. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
7. [Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing non-small cell lung cancer patients from healthy people].
Yang SY; Xiao XY; Zhang WG; Sun XZ; Zhang LJ; Zhang W; Zhou B; Yang DC; He DC
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):31-4. PubMed ID: 16638298
[TBL] [Abstract][Full Text] [Related]
8. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Han KQ; Huang G; Gao CF; Wang XL; Ma B; Sun LQ; Wei ZJ
Am J Clin Oncol; 2008 Apr; 31(2):133-9. PubMed ID: 18391596
[TBL] [Abstract][Full Text] [Related]
9. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer.
Chen Y; Zhang H; Xu A; Li N; Liu J; Liu C; Lv D; Wu S; Huang L; Yang S; He D; Xiao X
Lung Cancer; 2006 Oct; 54(1):95-102. PubMed ID: 16890323
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers.
Rathinam S; Ward DG; James ND; Rajesh PB
Interact Cardiovasc Thorac Surg; 2011 Jul; 13(1):3-6. PubMed ID: 21525028
[TBL] [Abstract][Full Text] [Related]
11. Accuracy and prognostic impact of a vessel invasion grading system for stage IA non-small cell lung cancer.
Hashizume S; Nagayasu T; Hayashi T; Hidaka S; Tsuchiya T; Tagawa T; Yamasaki N; Furukawa K; Matsumoto K; Miyazaki T
Lung Cancer; 2009 Sep; 65(3):363-70. PubMed ID: 19157635
[TBL] [Abstract][Full Text] [Related]
12. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
13. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
14. Detection of lung cancer in silicosis patients using a tumor-marker panel.
Schneider J
Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
[TBL] [Abstract][Full Text] [Related]
15. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
16. Biomarker identification in human pancreatic cancer sera.
Hanas JS; Hocker JR; Cheung JY; Larabee JL; Lerner MR; Lightfoot SA; Morgan DL; Denson KD; Prejeant KC; Gusev Y; Smith BJ; Hanas RJ; Postier RG; Brackett DJ
Pancreas; 2008 Jan; 36(1):61-9. PubMed ID: 18192883
[TBL] [Abstract][Full Text] [Related]
17. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
[TBL] [Abstract][Full Text] [Related]
18. Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry.
Li F; Qin X; Chen H; Qiu L; Guo Y; Liu H; Chen G; Song G; Wang X; Li F; Guo S; Wang B; Li Z
Rapid Commun Mass Spectrom; 2013 Jan; 27(1):24-34. PubMed ID: 23239314
[TBL] [Abstract][Full Text] [Related]
19. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
20. The importance of alpha-1 antitrypsin (alpha1-AT) and neopterin serum levels in the evaluation of non-small cell lung and prostate cancer patients.
El-Akawi ZJ; Abu-Awad AM; Sharara AM; Khader Y
Neuro Endocrinol Lett; 2010; 31(1):113-6. PubMed ID: 20150872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
